|Day Low/High||43.67 / 44.20|
|52 Wk Low/High||35.30 / 46.22|
I doubt this story. A London Sunday Times article suggests that Pfizer (PFE) considered acquiring AstraZeneca (AZN), but the talks stalled and will not resume. I am doubtful of this story and I have shorted AZN, +$6 in premarket trading as the compa...
Array is partnering with AstraZeneca and Novartis on a number of cancer drugs with trials soon getting underway that could transform the company by year end.
James Molloy, Managing Director at Janney Montgomery Scott explains why Actavis buying Forest Labs is a smart for Actavis and weighs in on speculation over whether or not Forest Labs is likely to receive a better offer.
The U.K.'s AstraZeneca and Germany's Bayer spend up to a combined $7.2 billion shoring up their portfolios. Laura Board reports from London.
Credit rating agency Standard & Poor's upgrades its credit outlook for the U.S. government to Stable from Negative.
Merger Monday begins with AstraZeneca buying Pearl, while Apple could announce iRadio and Google may purchase Waze as futures look up.
Stocks are up as AstraZeneca pays millions for Omthera, while Valeant buys Bausch & Lomb and Tiffany's earnings shine.
Hewlett-Packard announces a 10% increase in its quarterly dividend. Brittany Umar has details on that as well as a look at the day's other most searched trends on the Web.
LifeLock looks to be the best offering for the IPOs planned on Wednesday according to IPO Desltop President Francis Gaskins.
These companies are performing like champions, despite a weak British economy.
Stephanie Link, director of research at TheStreet, eliminated her position in Abbott to build a position in Bristol Meyers.
A look at some of the day's most searched topics on the Web, includingApple as the company shells out $60 million to settle its iPad namingdispute with Proview Technology.
Senior columnist Adam Feuerstein says M&A is the next big thing in biotech.
A look at the day's most searched trends on the Web, including AstraZeneca's purchase of Ardea Biosciences for $1.26 billion.
European headlines worried traders ahead of the open, as they await a raft of economic and retail reports.
The sector is in the doldrums, yet the prospects for these three names are quite strong.